[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568362":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":165,"collaborators":20,"id":167,"slug":168,"hasResults":169,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":169,"sex":175,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":20,"studyType":181,"phases":182,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},{"fullName":5,"class":6},"Precision BioSciences, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants in both Part 1 and 2 will receive a finite course of PBGENE-HBV.","EXPERIMENTAL","All participants will receive a finite course of multiple IV dose administrations of PBGENE-HBV. In Part 1, this will be done in a dose escalation manner which may be evaluated further in a Part 2 expansion cohort.",[13],"Biological: PBGENE-HBV",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","PBGENE-HBV","PBGENE-HBV is an in vivo gene editing intervention based on a novel proprietary ARCUS® platform designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Oby Sogbetun Medical Monitor, MD","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Precision Trial Manager","CONTACT","800-371-8953","ELIMINATE-B@precisionbiosciences.com",[32,53,73,88,104,125,146],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Massachusetts General Hospital\u002FHarvard University","RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-71.05977,42.35843,{"lat":44,"lon":43},[47,51],{"name":48,"role":28,"phone":49,"phoneExt":20,"email":50},"Raymond T Chung, MD","617-724-75","Chung.Raymond@mgh.harvard.edu",{"name":48,"role":52,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":54,"status":34,"city":55,"state":56,"zip":57,"country":56,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Hospital Beaujon","Clichy","France","92110","FR",{"type":41,"coordinates":60},[61,62],2.30952,48.90018,{"lat":62,"lon":61},[65,69,72],{"name":66,"role":28,"phone":67,"phoneExt":20,"email":68},"Tarik Asselah, MD","33140875514","tarik.asselah@aphp.fr",{"name":70,"role":28,"phone":67,"phoneExt":20,"email":71},"Stephanie Narguet","stephanie.narguet@aphp.fr",{"name":66,"role":52,"phone":20,"phoneExt":20,"email":20},{"facility":74,"status":34,"city":75,"state":75,"zip":20,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Queen Mary Hospital, The University of Hong Kong","Hong Kong","HK",{"type":41,"coordinates":78},[79,80],114.17469,22.27832,{"lat":80,"lon":79},[83,87],{"name":84,"role":28,"phone":85,"phoneExt":20,"email":86},"Man-Fung Yuen, MBBS, MD, PhD, DSc","852-2255 3579","mfyuen@hku.hk",{"name":84,"role":52,"phone":20,"phoneExt":20,"email":20},{"facility":89,"status":34,"city":90,"state":20,"zip":91,"country":92,"countryCode":93,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"ICS ARENSIA Exploratory Medicine SRL","Chisinau","2025","Moldova","MD",{"type":41,"coordinates":95},[96,97],28.85938,47.00902,{"lat":97,"lon":96},[100],{"name":101,"role":28,"phone":102,"phoneExt":20,"email":103},"Manager, Projects & Research Logistics","373-78883368","alexei.haceatrean@arensia-em.com",{"facility":105,"status":34,"city":106,"state":20,"zip":107,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"New Zealand Clinical Research","Auckland","1010","New Zealand","NZ",{"type":41,"coordinates":111},[112,113],174.76349,-36.84853,{"lat":113,"lon":112},[116,120,124],{"name":117,"role":28,"phone":118,"phoneExt":20,"email":119},"Edward Gane, MD","64-2-154-8371","EdGane@adhb.govt.nz",{"name":121,"role":28,"phone":122,"phoneExt":20,"email":123},"Sophie Townshend, Study Coordinator","64-9-373-3474","sophie.townshend@nzcr.co.nz",{"name":117,"role":52,"phone":20,"phoneExt":20,"email":20},{"facility":126,"status":34,"city":127,"state":128,"zip":129,"country":128,"countryCode":130,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"ARENSIA Exploratory Medicine","Bucharest","Romania","021105","RO",{"type":41,"coordinates":132},[133,134],26.10626,44.43225,{"lat":134,"lon":133},[137,141,145],{"name":138,"role":28,"phone":139,"phoneExt":20,"email":140},"Anca Streinu Cercel, MD","40722998425","anca.streinucercel@gmail.com",{"name":142,"role":28,"phone":143,"phoneExt":20,"email":144},"Coralia-Alexandra Caluian","40727193218","coralia.caluian@arensia-em.com",{"name":138,"role":52,"phone":20,"phoneExt":20,"email":20},{"facility":147,"status":34,"city":148,"state":128,"zip":149,"country":128,"countryCode":130,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Arensia Exploratory Medicine in collaboration with County Clinical Emergency Hospital","Cluj-Napoca","400006",{"type":41,"coordinates":151},[152,153],23.6,46.76667,{"lat":153,"lon":152},[156,160,164],{"name":157,"role":28,"phone":158,"phoneExt":20,"email":159},"Vlad-Andrei Ichim, MD","40751130280","vlad.ichim.ext@arensia-em.com",{"name":161,"role":28,"phone":162,"phoneExt":20,"email":163},"Emanuela Beni","40711912839","emanuela.beni@arensia-em.com",{"name":157,"role":52,"phone":20,"phoneExt":20,"email":20},{"type":166,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100568362","phase-1-phase-1-study-to-evaluate-safety-and-antiviral-activity-of-pbgene-hbv-in-adult-patients-with-chronic-hepatitis-b-100568362",false,"NCT06680232","Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B","A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B)","ELIMINATE-B","Key Inclusion Criteria:\n\n* Male or women of non-child bearing potential\n* BMI 18.0 to 35.0\n* Good overall health deemed by the study Investigator\n* CHB infection documented at least 12 months prior to screening\n* HBeAg-negative CHB\n* Must be virologically suppressed on current NA treatment\n\nKey Exclusion Criteria:\n\n* No history of cirrhosis of the liver\n* No current infections of Hepatitis A, D, and E, human immunodeficiency virus (type 1 and 2), and no history of or current hepatitis C. In addition, no other active infections deemed clinically relevant.\n* No signs of hepatocellular carcinoma\n* Not received an organ transplant\n* No malignancy within 5 years of screening, except for specific cancers that are cured by surgical resection (e.g., basal cell skin cancer)\n* No investigational agent received within 6 months of screening","ALL","18 Years","70 Years",{"count":179,"type":180},45,"ESTIMATED","INTERVENTIONAL",[183],"PHASE1","This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.",[186],"HEPATITIS B CHRONIC",[186,188,189,17],"Gene Therapy","Gene Editing","2026-08-21",{"date":192,"type":193},"2026-08-24","ACTUAL",{"date":195,"type":193},"2024-11-14",{"date":197,"type":180},"2027-06",{"name":5,"class":6},7]